Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2009

Open Access 01-02-2009 | Research

Biological behaviors and proteomics analysis of hybrid cell line EAhy926 and its parent cell line A549

Authors: Ze Jun Lu, Ya Qiong Ren, Guo Ping Wang, Qi Song, Mei Li, Sa Sa Jiang, Tao Ning, Yong Song Guan, Jin Liang Yang, Feng Luo

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2009

Login to get access

Abstract

Background

It is well established that cancer cells can fuse with endothelial cells to form hybrid cells spontaneously, which facilitates cancer cells traversing the endothelial barrier to form metastases. However, up to now, little is known about the biologic characteristics of hybrid cells. Therefore, we investigate the malignant biologic behaviors and proteins expression of the hybrid cell line EAhy926 with its parent cell line A549.

Methods

Cell counting and flow cytometry assay were carried out to assess cell proliferation. The number of cells attached to the extracellular matrix (Matrigel) was measured by MTT assay for the adhesion ability of cells. Transwell chambers were established for detecting the ability of cell migration and invasion. Tumor xenograft test was carried out to observe tumorigenesis of the cell lines. In addition, two-dimensional electrophoresis (2-DE) and mass spectrometry were utilized to identify differentially expressed proteins between in Eahy926 cells and in A549 cells.

Results

The doubling time of EAhy926 cell and A549 cell proliferation was 25.32 h and 27.29 h, respectively (P > 0.1). Comparing the phase distribution of cell cycle of EAhy926 cells with that of A549 cells, the percentage of cells in G0/G1 phase, in S phase and in G2/M phase was (63.7% ± 2.65%) VS (60.0% ± 3.17%), (15.4% ± 1.52%) VS (13.8% ± 1.32%), and (20.9% ± 3.40%) VS (26.3% ± 3.17%), respectively (P > 0.05). For the ability of cell adhesion of EAhy926 cells and A549 cells, the value of OD in Eahy926 cells was significantly higher than that in A549 cells (0.3236 ± 0.0514 VS 0.2434 ± 0.0390, P < 0.004). We also found that the migration ability of Eahy926 cells was stronger than that of A549 cells (28.00 ± 2.65 VS 18.00 ± 1.00, P < 0.01), and that the invasion ability of Eahy926 cells was significantly weak than that of A549 cells (15.33 ± 0.58 VS 26.67 ± 2.52, P < 0.01). In the xenograft tumor model, expansive masses of classic tumor were found in the A549 cells group, while subcutaneous inflammatory focuses were found in the EAhy926 cells group. Besides, twenty-eight proteins were identified differentially expressed between in EAhy926 cells and in A549 cells by proteomics technologies.

Conclusion

As for the biological behaviors, the ability of cell proliferation in Eahy926 cells was similar to that in A549 cells, but the ability in adhesion and migration of Eahy926 cells was higher. In addition, Eahy926 cells had weaker ability in invasion and could not form tumor mass. Furthermore, there were many differently expressed proteins between hybrid cell line Eahy926 cells and A549 cells, which might partly account for some of the differences between their biological behaviors at the molecular level. These results may help to understand the processes of tumor angiogenesis, invasion and metastasis, and to search for screening method for more targets for tumor therapy in future.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL: Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA. 2000, 97 (26): 14608-13. 10.1073/pnas.97.26.14608.CrossRef Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL: Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA. 2000, 97 (26): 14608-13. 10.1073/pnas.97.26.14608.CrossRef
2.
go back to reference Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent PS, Meltzer , Mary JC: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999, 155 (3): 739-52.CrossRef Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent PS, Meltzer , Mary JC: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999, 155 (3): 739-52.CrossRef
3.
go back to reference Mortensen K, Lichtenberg J, Thomsen PD, Larsson LI: Spontaneous fusion between cancer cells and endothelial cells. Cell Mol Life Sci. 2004, 61 (16): 2125-31. 10.1007/s00018-004-4200-2.CrossRef Mortensen K, Lichtenberg J, Thomsen PD, Larsson LI: Spontaneous fusion between cancer cells and endothelial cells. Cell Mol Life Sci. 2004, 61 (16): 2125-31. 10.1007/s00018-004-4200-2.CrossRef
4.
go back to reference Yan L, Moses MA, Huang S, Ingber DE: Adhesion-dependent control of matrix metalloproteinase-2 activation in human capillary endothelial cells. J Cell Sci. 2000, 3979-87. Pt 22 Yan L, Moses MA, Huang S, Ingber DE: Adhesion-dependent control of matrix metalloproteinase-2 activation in human capillary endothelial cells. J Cell Sci. 2000, 3979-87. Pt 22
5.
go back to reference Edgell CJ, McDonald CC, Graham JB: Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA. 1983, 80 (12): 3734-7. 10.1073/pnas.80.12.3734.CrossRef Edgell CJ, McDonald CC, Graham JB: Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA. 1983, 80 (12): 3734-7. 10.1073/pnas.80.12.3734.CrossRef
6.
go back to reference Bouïs D, Hospers GA, Meijer C, Molema G, Mulder NH: Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis. 2001, 4 (2): 91-102. 10.1023/A:1012259529167.CrossRef Bouïs D, Hospers GA, Meijer C, Molema G, Mulder NH: Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis. 2001, 4 (2): 91-102. 10.1023/A:1012259529167.CrossRef
7.
go back to reference Nicosia RF, Tchao R, Leighton J: Interactions between newly formed endothelial channels and carcinoma cells in plasma clot culture. Clin Exp Metastasis. 1986, 4 (2): 91-104. 10.1007/BF00119076.CrossRef Nicosia RF, Tchao R, Leighton J: Interactions between newly formed endothelial channels and carcinoma cells in plasma clot culture. Clin Exp Metastasis. 1986, 4 (2): 91-104. 10.1007/BF00119076.CrossRef
8.
go back to reference Phillips PG, Birnby LM, Narendran A: Hypoxia induces capillary network formation in cultured bovine pulmonary microvessel endothelial cells. Am J Physiol. 1995, 268 (5 Pt 1): L789-800. Phillips PG, Birnby LM, Narendran A: Hypoxia induces capillary network formation in cultured bovine pulmonary microvessel endothelial cells. Am J Physiol. 1995, 268 (5 Pt 1): L789-800.
9.
go back to reference Zhang W, Ce Mattia JA, Song H, Couldwell WT: Communication between malignant glioma cells and vascular endothelial cells through gap junctions. J Neurosurg. 2003, 98 (4): 846-53.CrossRef Zhang W, Ce Mattia JA, Song H, Couldwell WT: Communication between malignant glioma cells and vascular endothelial cells through gap junctions. J Neurosurg. 2003, 98 (4): 846-53.CrossRef
10.
go back to reference Brown J, Reading SJ, Jones S, Fitchett CJ, Howl J, Martin A, Longland CL, Michelangeli F, Dubrova YE, Brown CA: Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: a comparison with the human bladder cancer derived epithelial cell lineT24/83. Lab Investigation. 2000, 80 (1): 37-45. 10.1038/labinvest.3780006.CrossRef Brown J, Reading SJ, Jones S, Fitchett CJ, Howl J, Martin A, Longland CL, Michelangeli F, Dubrova YE, Brown CA: Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: a comparison with the human bladder cancer derived epithelial cell lineT24/83. Lab Investigation. 2000, 80 (1): 37-45. 10.1038/labinvest.3780006.CrossRef
11.
go back to reference Imamura T, Mitsui Y: Heparan sulfate and heparin as a potentiator or a suppressor of growth of normal and transformed vascular endothelial cells. Experimental Cell Research. 1987, 172 (1): 92-100. 10.1016/0014-4827(87)90096-6.CrossRef Imamura T, Mitsui Y: Heparan sulfate and heparin as a potentiator or a suppressor of growth of normal and transformed vascular endothelial cells. Experimental Cell Research. 1987, 172 (1): 92-100. 10.1016/0014-4827(87)90096-6.CrossRef
12.
go back to reference Kilic B, Kruse M, Stahlmann R: The in vitro effects of quinupristin/dalfopristin, erythromycin and levofloxacin at low concentrations on the expression of different cell adhesion molecules on the surface of endothelial cells (Eahy926). Toxicology. 2006, 218 (1): 30-8. 10.1016/j.tox.2005.09.014.CrossRef Kilic B, Kruse M, Stahlmann R: The in vitro effects of quinupristin/dalfopristin, erythromycin and levofloxacin at low concentrations on the expression of different cell adhesion molecules on the surface of endothelial cells (Eahy926). Toxicology. 2006, 218 (1): 30-8. 10.1016/j.tox.2005.09.014.CrossRef
13.
go back to reference Heikkilä P, Teronen O, Moilanen M, Konttinen YT, Hanemaaijer R, Laitinen M, Maisi P, Pluijm G, Bartlett JD, Salo T, Sorsa T: Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anti-Cancer Drugs. 2002, 13 (3): 245-54. 10.1097/00001813-200203000-00006.CrossRef Heikkilä P, Teronen O, Moilanen M, Konttinen YT, Hanemaaijer R, Laitinen M, Maisi P, Pluijm G, Bartlett JD, Salo T, Sorsa T: Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anti-Cancer Drugs. 2002, 13 (3): 245-54. 10.1097/00001813-200203000-00006.CrossRef
14.
go back to reference Tressler RJ, Updyke TV, Yeatman T, Nicolson GL: Extracellular annexin II is associated with divalent cation-dependent tumor cell-endothelial cell adhesion of metastatic RAW117 large-cell lymphoma cells. J Cell Biochem. 1993, 53 (3): 265-76. 10.1002/jcb.240530311.CrossRef Tressler RJ, Updyke TV, Yeatman T, Nicolson GL: Extracellular annexin II is associated with divalent cation-dependent tumor cell-endothelial cell adhesion of metastatic RAW117 large-cell lymphoma cells. J Cell Biochem. 1993, 53 (3): 265-76. 10.1002/jcb.240530311.CrossRef
15.
go back to reference Filipenko NR, MacLeod TJ, Yoon CS, Waisman DM: Annexin A2 is a novel RNA-binding protein. J Biol Chem. 2004, 279 (10): 8723-31. 10.1074/jbc.M311951200.CrossRef Filipenko NR, MacLeod TJ, Yoon CS, Waisman DM: Annexin A2 is a novel RNA-binding protein. J Biol Chem. 2004, 279 (10): 8723-31. 10.1074/jbc.M311951200.CrossRef
16.
go back to reference Wang M, Tang J, Liu S, Yoshida D, Teramoto A: Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas. J Neurooncol. 2005, 71 (1): 3-7. 10.1007/s11060-004-9163-5.CrossRef Wang M, Tang J, Liu S, Yoshida D, Teramoto A: Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas. J Neurooncol. 2005, 71 (1): 3-7. 10.1007/s11060-004-9163-5.CrossRef
17.
go back to reference Levicar N, Strojnik T, Kos J, Dewey RA, Pilkington GJ, Lah TT: Lysosomal enzymes, cathepsins in brain tumour invasion. J Neurooncol. 2002, 58 (1): 21-32. 10.1023/A:1015892911420.CrossRef Levicar N, Strojnik T, Kos J, Dewey RA, Pilkington GJ, Lah TT: Lysosomal enzymes, cathepsins in brain tumour invasion. J Neurooncol. 2002, 58 (1): 21-32. 10.1023/A:1015892911420.CrossRef
18.
go back to reference Czyzewska J, Guziñska-Ustymowicz K, Kemona A, Bandurski R: The expression of matrix metalloproteinase 9 and cathepsin B in gastric carcinoma is associated with lymph node metastasis, but not with postoperative survival. Folia Histochem Cytobiol. 2008, 46 (1): 57-64. 10.2478/v10042-008-0007-6.CrossRef Czyzewska J, Guziñska-Ustymowicz K, Kemona A, Bandurski R: The expression of matrix metalloproteinase 9 and cathepsin B in gastric carcinoma is associated with lymph node metastasis, but not with postoperative survival. Folia Histochem Cytobiol. 2008, 46 (1): 57-64. 10.2478/v10042-008-0007-6.CrossRef
19.
go back to reference Bradley WH, Lima PH, Rodgers L, Blomquist CH, Downs LS: Endometrial carcinoma expresses an increased cathepsin B/D ratio. Gynecol Oncol. 2008, 108 (1): 84-9. 10.1016/j.ygyno.2007.08.094.CrossRef Bradley WH, Lima PH, Rodgers L, Blomquist CH, Downs LS: Endometrial carcinoma expresses an increased cathepsin B/D ratio. Gynecol Oncol. 2008, 108 (1): 84-9. 10.1016/j.ygyno.2007.08.094.CrossRef
20.
go back to reference Hardy B, Battler A, Weiss C, Kudasi O, Raiter A: Therapeutic angiogenesis of mouse hind limb ischemia by novel peptide activating GRP78 receptor on endothelial cells. Biochem. 2008, 75 (4): 891-9. Hardy B, Battler A, Weiss C, Kudasi O, Raiter A: Therapeutic angiogenesis of mouse hind limb ischemia by novel peptide activating GRP78 receptor on endothelial cells. Biochem. 2008, 75 (4): 891-9.
21.
go back to reference Rauschert N, Brändlein S, Holzinger E, Hensel F, Müller-Hermelink HK, Vollmers HP: A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab Invest. 2008, 88 (4): 375-86. 10.1038/labinvest.2008.2.CrossRef Rauschert N, Brändlein S, Holzinger E, Hensel F, Müller-Hermelink HK, Vollmers HP: A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab Invest. 2008, 88 (4): 375-86. 10.1038/labinvest.2008.2.CrossRef
22.
go back to reference Langer R, Feith M, Siewert JR, Wester HJ, Hoefler H: Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer. 2008, 10 (8): 70-10.1186/1471-2407-8-70.CrossRef Langer R, Feith M, Siewert JR, Wester HJ, Hoefler H: Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer. 2008, 10 (8): 70-10.1186/1471-2407-8-70.CrossRef
23.
go back to reference Wiener F, Klein G, Harris H: The analysis of malignancy by cell fusion. V. Further evidence of the ability of normal diploid cells to suppress malignancy. J Cell Sci. 1974, 15 (1): 177-83. Wiener F, Klein G, Harris H: The analysis of malignancy by cell fusion. V. Further evidence of the ability of normal diploid cells to suppress malignancy. J Cell Sci. 1974, 15 (1): 177-83.
24.
go back to reference Harris H: The analysis of malignancy by cell fusion: the position in 1988. Cancer Res. 1988, 48 (12): 3302-6. Harris H: The analysis of malignancy by cell fusion: the position in 1988. Cancer Res. 1988, 48 (12): 3302-6.
25.
go back to reference Anderson MJ, Stanbridge EJ: Tumor suppressor genes studied by cell hybridization and chromosome transfer. FASEB J. 1993, 7 (10): 826-33. Anderson MJ, Stanbridge EJ: Tumor suppressor genes studied by cell hybridization and chromosome transfer. FASEB J. 1993, 7 (10): 826-33.
26.
go back to reference Saxon PJ, Srivatsan ES, Stanbridge EJ: Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. EMBO J. 1986, 5 (13): 3461-6. Saxon PJ, Srivatsan ES, Stanbridge EJ: Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. EMBO J. 1986, 5 (13): 3461-6.
27.
go back to reference Stanbridge EJ, Der CJ, Doersen CJ, Nishimi RY, Peehl DM, Weissman BE, Wilkinson JE: Human cell hybrids: analysis of transformation and tumorigenicity. Science. 1982, 215 (4530): 252-9. 10.1126/science.7053574.CrossRef Stanbridge EJ, Der CJ, Doersen CJ, Nishimi RY, Peehl DM, Weissman BE, Wilkinson JE: Human cell hybrids: analysis of transformation and tumorigenicity. Science. 1982, 215 (4530): 252-9. 10.1126/science.7053574.CrossRef
Metadata
Title
Biological behaviors and proteomics analysis of hybrid cell line EAhy926 and its parent cell line A549
Authors
Ze Jun Lu
Ya Qiong Ren
Guo Ping Wang
Qi Song
Mei Li
Sa Sa Jiang
Tao Ning
Yong Song Guan
Jin Liang Yang
Feng Luo
Publication date
01-02-2009
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2009
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-28-16

Other articles of this Issue 1/2009

Journal of Experimental & Clinical Cancer Research 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine